Patient Support Hub
Welcome to the Patient Support Hub, powered by PathLink — a secure platform created exclusively for people with cancer and caregivers. The Hub connects you with peer support and trusted resources across every stage of the cancer journey — from diagnosis and treatment to long-term survivorship.
Developed through a strategic partnership between the Asian Fund for Cancer Research Limited and the National Foundation for Cancer Research (NFCR), a leading U.S. cancer research organization with more than 53 years of dedication to advancing cancer research worldwide.
PathLink Journey is privacy-first by design
AI-powered guidance for treatment pathways, clinical trial resources, and questions to discuss with your care team.
Connected support system
Connect with others who get it. Share experiences, ask questions, and find support in your cancer community.
Verified, guideline-based content
Access the latest oncology guidelines from the world’s leading cancer organizations, right when you need them.
Trusted medical fundraising
Trusted Fundraising to secure financial support when you need it most
Why this Hub Matters?
50.7%
of all new cancer cases worldwide occur in Asia
56.5%
of all cancer deaths worldwide occur in Asia
People with cancer and caregivers often face complex treatment decisions, uneven access to resources, and unmet support needs.
The Hub brings world-leading, evidence-based cancer knowledge closer to people with cancer and caregivers — powered by AI and grounded in internationally recognized oncology standards, such as NCCN and ASCO, helping them navigate cancer journey with clarity, confidence, and trusted guidance.
Supporting People with Cancer and Caregivers
Asian Fund for Cancer Research Limited is committed to improving access to cancer information and empowering people with cancer and caregivers across Asia and around the world. Through our partnership with NFCR and the PathLink platform, we aim to make reliable cancer information more accessible and easier to navigate for everyone.
